AB SCIEX UK LIMITED

Their core work

AB SCIEX UK LIMITED is the British subsidiary of SCIEX (a Danaher company), one of the world's foremost manufacturers of mass spectrometry instruments and analytical software. Their core business is designing and supplying precision analytical tools used to identify, quantify, and characterize molecules — proteins, lipids, pharmaceuticals, and nanomaterials — across pharmaceutical, biotech, food safety, and materials research. In EU projects they participate as an industrial partner, bringing commercial-grade instrumentation and deep application expertise that most academic consortia cannot replicate in-house. Their involvement spans both life science analytics (protein and lipid adduct analysis) and materials characterization (nanomaterial risk assessment), reflecting the broad applicability of mass spectrometry technology.

What they specialise in

How they've shifted over time

AB SCIEX's early H2020 engagement (2015) centred on biological mass spectrometry — specifically the analysis of protein-lipid adducts within a researcher training network, anchoring them firmly in life sciences and proteomics. By 2017 their participation had moved toward nanomaterial characterization and regulatory risk assessment within a research innovation action, signalling an expansion into materials science and safety testing. With only two projects and no keyword metadata available, this trajectory is plausible but should be treated as directional rather than conclusive.

AB SCIEX appears to be broadening the application of its analytical platforms from pure life science research toward materials safety and regulatory characterization — a commercially strategic direction as nanomaterial regulation tightens across Europe.

How they like to work

AB SCIEX holds zero coordinator roles across all H2020 participation, consistently joining as a specialist industrial partner rather than a project driver. Both projects were large pan-European networks, which explains the unusually high partner count (53 unique partners) for just two projects — they enter ready-built consortia rather than assembling their own. This pattern suggests they are most useful to a consortium builder as a named industrial contributor who provides instrument access, validation support, and commercial credibility, not as an administrative or scientific lead.

Across two projects AB SCIEX UK has touched 53 unique partners spanning 13 countries — a disproportionately wide network that reflects participation in large, multi-node European training and research networks rather than bilateral collaborations. No geographic concentration is evident from the data, suggesting broad pan-European exposure.

What sets them apart

As the commercial arm of a global mass spectrometry leader, AB SCIEX UK brings something most academic partners simply cannot: immediate access to validated, production-grade analytical instrumentation and the application specialists who know it. For consortia working on analytical method development, characterization standards, or training programmes, having SCIEX as a named partner also adds industrial relevance and commercial pathway credibility that strengthens a proposal. Their dual presence in both life sciences and nanomaterials means they can serve as an analytical backbone across a wider range of research domains than a single-discipline academic lab.

Highlights from their portfolio

• ACEnano
  The only project where AB SCIEX received direct EC funding (EUR 270,000), this RIA on nanomaterial risk characterization represents their deepest funded engagement and their clearest entry into the materials safety domain.
• MASSTRPLAN
  An MSCA Innovative Training Network explicitly built around mass spectrometry for protein-lipid adduct analysis — the project most directly aligned with AB SCIEX's core commercial technology and life science user base.